47 completed, 13 unknown, 7 recruiting, 7 terminated. 87 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 87 | Completed 47, Unknown 13, Recruiting 7, Terminated 7, Withdrawn 6, Active not recruiting 3, Not yet recruiting 3, Enrolling by invitation 1 |
Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2026-10-01 | 2026-09-18 |
| Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease Prophylactic Transfusion Intervention group: Transfusion, Control group - Sickle Cell Disease, Pregnancy Related | Phase 4 | Withdrawn | Emory University | 2026-09-01 | 2026-10-19 | |
| Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm) - Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD) | Phase 4 | Not yet recruiting | University of Mississippi Medical Center | 400 | 2026-08-01 | 2026-07-06 |
| Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions - Sickle Cell Disease (SCD) | Phase 4 | Recruiting | Swiss Tropical & Public Health Institute | 120 | 2026-07-27 | 2026-10-05 |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease Depot medroxyprogesterone acetate (DMPA) - Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 4 | Recruiting | University of Pennsylvania | 65 | 2025-06-26 | 2026-05-28 |
| Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) PK-optimized oral hydroxyurea at MTD until 15 years of age. - Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 50 | 2024-12-19 | 2025-09-16 |
| Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease Ketorolac - Sickle Cell Disease, Sickle Cell Crisis | Phase 4 | Not yet recruiting | Children's Blood and Cancer Center at Dell Children's Medical Center | 102 | 2024-09-30 | 2024-08-30 |
| Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia Tablet Metformin (Group A), Tablet Hydroxyurea (Group B) - Transfusion Dependent Beta-thalassemia | Phase 4 | Completed | Bahria University | 96 | 2024-09-16 | 2026-04-28 |
| Stroke Prevention in Nigeria 2 Trial Hydroxyurea - Sickle Cell Disease, Stroke | Phase 4 | Recruiting | Vanderbilt University Medical Center | 220 | 2024-08-05 | 2026-03-05 |
| Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). - Vivax Malaria, G6PD Deficiency | Phase 4 | Recruiting | Menzies School of Health Research | 100 | 2024-05-17 | 2026-03-12 |
| Voxelotor Brain Oxygenation and Neurocognitive Study Voxelotor Oral Tablet - Sickle Cell Disease | Phase 4 | Withdrawn | Pfizer | 2023-08-09 | 2024-08-09 | |
| Effects of the Contraceptive Implant in Women With Sickle Cell Disease Nexplanon 68 MG Drug Implant - Sickle Cell Disease | Phase 4 | Active not recruiting | University of Pennsylvania | 22 | 2023-08-02 | 2026-06-12 |
| A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study Mitapivat - Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 4 | Enrolling by invitation | Agios Pharmaceuticals, Inc. | 55 | 2023-07-06 | 2026-10-28 |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India Luspatercept - Anemia | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 85 | 2023-06-05 | 2026-08-31 |
| Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient Clonidine - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 4 | Unknown | Centre Hospitalier Universitaire Saint Pierre | 40 | 2023-04-25 | 2023-05-08 |
| The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study Luspatercept Injectable Product - Thalassemia Major, Transfusion-dependent Anemia | Phase 4 | Unknown | Sun Yat-sen University | 20 | 2022-07-01 | 2022-07-18 |
| Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients L-Glutamine, Oral Powder for Reconstitution, Standard of care - Sickle Cell Disease | Phase 4 | Completed | Ain Shams University | 60 | 2022-01-04 | 2024-01-09 |
| Ketamine Infusion for Sickle Cell Pain Crisis Ketamine, Pain management - Anemia; Sickle-Cell, With Crisis, Acute Pain | Phase 4 | Withdrawn | Duke University | 2022-01-01 | 2022-01-14 | |
| Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age Trumenba - Meningococcal Vaccine | Phase 4 | Completed | Pfizer | 53 | 2021-08-18 | 2024-10-16 |
Showing 20 of 87. Sign in to see all of them.
Anemia, Sickle Cell (38) · Thalassemia (17) · beta-Thalassemia (17) · Iron Overload (10) · Vaso-Occlusive Crises (10) · Glucosephosphate Dehydrogenase Deficiency (6) · Hepatitis C (6) · Anemia (4) · Hemolysis (4) · Agnosia (3) · Fibrosis (3) · Hemoglobinuria, Paroxysmal (3) · Pain (3) · Acute Pain (2)
Hemic and Lymphatic Diseases (87) · Hematologic Diseases (85) · Anemia (83) · Anemia, Hemolytic, Congenital (77) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (77) · Genetic Diseases, Inborn (77) · Hemoglobinopathies (70) · Metabolic Diseases (16) · Nutritional and Metabolic Diseases (16) · Pathological Conditions, Signs and Symptoms (14) · Thalassemia (14) · Infections (10) · Iron Metabolism Disorders (10) · Signs and Symptoms (8)
Deferasirox (6) · Deferiprone (6) · Morphine (6) · Hydroxyurea (5) · Ketamine (5) · Deferoxamine (4) · Ribavirin (4) · Tacrolimus (4) · Methotrexate (3) · Mycophenolic Acid (3) · Primaquine (3) · Saline Solution (3) · eculizumab (3) · peginterferon alfa-2a (3) · voxelotor (3)
Novartis Pharmaceuticals (10) · Alexion Pharmaceuticals, Inc. (3) · ApoPharma (3) · Duke University (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Pfizer (3) · Ain Shams University (2) · Assistance Publique - Hôpitaux de Paris (2) · Children's Hospital Medical Center, Cincinnati (2) · Fakultas Kedokteran Universitas Indonesia (2) · First Affiliated Hospital of Guangxi Medical University (2) · Montefiore Medical Center (2) · Peking Union Medical College Hospital (2) · The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine (2) · University of Pennsylvania (2)
United States (29) · China (11) · Egypt (9) · France (6) · Italy (6) · Turkey (Türkiye) (6) · Brazil (5) · United Kingdom (5) · Belgium (4) · Canada (4) · Lebanon (4) · Greece (3) · India (3) · Indonesia (3) · Israel (3)
Fatma SE Ebeid, MD (2) · Janet Kwiatkowski, MD (2) · Yanfang Li, PhD (2) · Yongrong Lai, MD (2) · Alejandro Balestracci, MD, PhD (1) · Alicia Chang, MD (1) · Andrea Roe, MD MPH (1) · Antonio Piga, M.D. (1) · Arjunan Ganesh, MD (1) · Ayesha Khan, MBBS MPhil (1) · Bamidele O Tayo, PhD (1)
PMID 10100293, PMID 16273116, PMID 16737942, PMID 18298856, PMID 19075138, PMID 19236376, PMID 19407319, PMID 19724055, PMID 20163377, PMID 2082307, PMID 2666928, PMID 2689472, PMID 27288381, PMID 27993418, PMID 28238158, PMID 29155313, PMID 29756251, PMID 29794277, PMID 30663794, PMID 30871496, PMID 31723837, PMID 32179526, PMID 33025690, PMID 33270832, PMID 34847228, PMID 35166922, PMID 36018224, PMID 37247190, PMID 37807937, PMID 37975597, PMID 38401036, PMID 39301879, PMID 39428602, PMID 41730859, PMID 9620101
2009 (1), 2014 (1), 2018 (1), 2019 (1), R01HL175726 (1), U01NS129143 (1), U54HL070588 (1)